Bank of America just raised its EUR/USD forecast
Jasper Therapeutics, Inc. (JSPR) stock has hit a 52-week low, trading at $4.99, down 21% in the past week alone. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions, with the price now 83% below its 52-week high of $31.01. This new low comes as a stark contrast to its performance over the past year, with the stock declining nearly 68% over the past twelve months. Investors are closely monitoring the stock as it navigates through the current market conditions, which have been particularly unforgiving to the healthcare sector. While the stock shows high volatility with a beta of 2.12, analyst price targets range from $40 to $80, suggesting potential upside according to InvestingPro data. The company’s journey to this 52-week low reflects broader industry trends and investor sentiment, as market participants reassess the value and prospects of healthcare investments in a volatile economic landscape.
In other recent news, Jasper Therapeutics has been the focus of several analyst notes following initial data from their BEACON study. RBC Capital Markets reduced its price target for the company to $48, maintaining an Outperform rating. The decision was influenced by the BEACON study’s initial findings, which led to significant volatility in the company’s stock. Despite the reduction, RBC remains optimistic about Jasper’s future, citing potential upcoming developments as a chance to reassess the company’s valuation.
Simultaneously, BTIG analyst Justin Zelin revised Jasper’s price target to $64 from the previous $90 while sustaining a Buy rating. Zelin highlighted the promising results from a 240mg single-dose of Jasper’s briquilimab, which showed a 100% complete response rate maintained through eight weeks. Despite a decrease in stock value, BTIG reiterated its Buy rating, citing upcoming catalysts that could positively impact Jasper.
On the other hand, H.C. Wainwright analyst Emily Bodnar confirmed a Buy rating and a $40.00 price target on Jasper Therapeutics shares. Bodnar’s analysis indicates that the UAS7=0 rates for briquilimab were at least on par with those observed in Phase 1b and Phase 2 studies of barzolvolimab, a comparable treatment developed by Celldex Therapeutics (NASDAQ:CLDX). Furthermore, BMO Capital Markets maintained their Outperform rating on Jasper Therapeutics with a steady price target of $63.00, expressing continued optimism despite the company’s shares plunging approximately 55% after preliminary data from the BEACON trial.
In light of these developments, Jasper Therapeutics remains a key player to watch in the industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.